HUMDF (Hua Medicine) YoY EBITDA Growth : 14.29% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Hua Medicine's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 14.29%.

Hua Medicine's EBITDA per Share for the six months ended in Dec. 2024 was $-0.01.

Hua Medicine YoY EBITDA Growth Historical Data

The historical data trend for Hua Medicine's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hua Medicine YoY EBITDA Growth Chart

Hua Medicine Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

4.76

20.00

47.92

4.00

-20.83

Hua Medicine Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
YoY EBITDA Growth	Get a 7-Day Free Trial												47.83	28.57	-16.67	-70.00	14.29

Hua Medicine YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Hua Medicine's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(-0.029	-	-0.024)	/	\| -0.024 \|
=	-20.83 %

Hua Medicine's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2024 )
=	(EBITDA per Share (Q: Dec. 2024 )	-	EBITDA per Share (Q: Dec. 2023 ))	/	\| EBITDA per Share (Q: Dec. 2023 )) \|
=	(-0.012	-	-0.014)	/	\| -0.014 \|
=	14.29 %

Hua Medicine YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Hua Medicine's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Hua Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (OTCPK:HUMDF) » Definitions » YoY EBITDA Growth

Traded in Other Exchanges

02552:Hong Kong

Address

Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203

Website

https://www.huamedicine.com

Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC.